Idenix, Novartis seek approval for chronic hepatitis B treatment
Idenix Pharmaceuticals Inc. and Novartis Pharmaceuticals Corp. said they have applied to the Food and Drug Administration for approval of a treatment for chronic hepatitis B. (Full article: 360 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
